User profiles for Roberto Ria

Roberto Ria

Universitą degli Studi di Bari "Aldo Moro"
Verified email at uniba.it
Cited by 13500

Mast cell contribution to angiogenesis related to tumour progression

…, E Crivellato, AM Roccaro, R Ria… - Clinical & …, 2004 - Wiley Online Library
The current wisdom is that tumours are endowed with an angiogenic capability and that their
growth, invasion and metastasis are angiogenesis dependent. It is now well documented …

Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma

…, M Minischetti, M Iurlaro, R Ria… - Blood, The Journal …, 1999 - ashpublications.org
To assess whether the progression of plasma cell tumors is accompanied by angiogenesis
and secretion of matrix-degrading enzymes, bone marrow biopsy specimens from 20 patients …

Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo

D Ribatti, M Presta, A Vacca, R Ria… - Blood, The Journal …, 1999 - ashpublications.org
Hematopoietic and endothelial cell lineages share common progenitors. Accordingly, cytokines
formerly thought to be specific for the hematopoietic system have been shown to affect …

Metronomic chemotherapy from rationale to clinical studies: a dream or reality?

…, A Licchetta, D Santini, M Scartozzi, R Ria… - Critical reviews in …, 2015 - Elsevier
Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic
drug for a long time with no extended drug-free breaks. It was developed to overcome drug …

[HTML][HTML] Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma

…, A Melaccio, AG Solimando, A Lamanuzzi, R Ria… - Cells, 2020 - mdpi.com
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the
treatment of multiple myeloma (MM). Although recent data have demonstrated very promising …

[PDF][PDF] Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for …

…, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria… - J Clin Oncol, 2010 - academia.edu
Purpose The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of
care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the …

[PDF][PDF] Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

…, F Gentilini, C Crippa, M Galli, C Nozzoli, R Ria… - Journal of Clinical …, 2011 - iris.unito.it
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases
the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we …

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

…, D Rossi, M Cavalli, M Genuardi, R Ria… - Blood, The Journal …, 2010 - ashpublications.org
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance
treatment with bortezomib-thalidomide demonstrated superior efficacy compared with …

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

…, F Patriarca, M Offidani, R Ria… - Blood, The Journal …, 2011 - ashpublications.org
Complete response (CR) was an uncommon event in elderly myeloma patients until novel
agents were combined with standard oral melphalan-prednisone. This analysis assesses the …

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

…, V Callea, M Montanaro, R Ria… - Blood, The Journal …, 2008 - ashpublications.org
The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT)
in newly diagnosed patients with myeloma showed significantly higher response rate and …